Search Results

You are looking at 111 - 120 of 388 items for :

  • Refine by Access: All x
Clear All
Full access

Making the Grade: The Impact of Low-Grade Toxicities on Patient Preference for Treatment With Novel Agents

Emily H. Castellanos, Sheau-chiann Chen, Hillary Drexler, and Leora Horn

toxicities of nausea, vomiting, or diarrhea on a chronic basis, and more than 15% would decline potentially curative treatment if faced with chronic grade 1 nausea, vomiting, or diarrhea. Thus, it may be that certain types of chronic toxicity, even if “low

Full access

Gastric MALT Lymphoma Treated With Primary Radiotherapy in the Setting of Autoimmune Disease

Chelsea C. Pinnix, Valerie Reed, and Bouthaina Dabaja

abdominal pain resolved after recent administration of a proton pump inhibitor. She denied gastrointestinal symptoms. She denied melena, nausea, vomiting, anorexia, unintentional weight loss, fevers, and night sweats. Her medical history was notable for HT

Full access

A Patient With Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib

Jonathan W. Riess, Seema Nagpal, Joel W. Neal, and Heather A. Wakelee

partial response and symptomatic improvement, while working full-time and traveling. This continued for 10 months, but he then developed headache, confusion, nausea, and vomiting. An MRI of the brain revealed enhancement of the leptomeninges consistent

Full access

New Meets Old: A Case Study and Review of Novel Therapeutics for the Treatment of CLL in Older Patients

Neel K. Gupta and Charalambos Andreadis

%. 19 The most common nonhematologic adverse events were diarrhea (50%), fatigue (32%), and nausea (18%). Grade 3 and 4 hematologic adverse events included neutropenia (15%), thrombocytopenia (6%), and anemia (6%). An adverse event leading to

Full access

Clinical Impact of Local Progression in Pancreatic Cancer

Nicholas Cardillo, Daniel M. Seible, Katherine E. Fero, Andrew R. Bruggeman, Reith R. Sarkar, Alexa Azuara, Daniel R. Simpson, and James D. Murphy

, disease complications, and circumstances of death. Disease-related symptoms recorded included nausea and vomiting, gastrointestinal bleeding, cancer-related pain, biliary and gastrointestinal obstructions, thromboembolic events, and depression. Disease

Full access

Updates in the Treatment of Metastatic Colorectal Cancer

Presented by: Midhun Malla, Katrina S. Pedersen, and Aparna R. Parikh

most common tucatinib-related AEs were diarrhea, fatigue, nausea, and dermatitis. The FDA granted accelerated approval for this combination in January 2023. Fam-Trastuzumab-Deruxtecan-nxki (T-DXd) Dr. Malla discussed the use of the antibody

Full access

Multidisciplinary Management of Advanced Kidney Cancer

Presented by: Chad A. LaGrange, M. Dror Michaelson, and Colleen H. Tetzlaff

ipilimumab/nivolumab. The patient was treated with cabozantinib 60 mg/day. The most common side effects with this drug are nausea, vomiting, diarrhea, decreased appetite, fatigue, hypertension, and hand-foot syndrome. With grades 1 and tolerable grade 2

Full access

Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology

Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, David Cooke, Carlos Corvera, Prajnan Das, Peter C. Enzinger, Thomas Enzler, Farhood Farjah, Hans Gerdes, Michael Gibson, Patrick Grierson, Wayne L. Hofstetter, David H. Ilson, Shadia Jalal, Rajesh N. Keswani, Sunnie Kim, Lawrence R. Kleinberg, Samuel Klempner, Jill Lacy, Frank Licciardi, Quan P. Ly, Kristina A. Matkowskyj, Michael McNamara, Aaron Miller, Sarbajit Mukherjee, Mary F. Mulcahy, Darryl Outlaw, Kyle A. Perry, Jose Pimiento, George A. Poultsides, Scott Reznik, Robert E. Roses, Vivian E. Strong, Stacey Su, Hanlin L. Wang, Georgia Wiesner, Christopher G. Willett, Danny Yakoub, Harry Yoon, Nicole R. McMillian, and Lenora A. Pluchino

patients achieved a complete response, partial response, and stable disease. The most frequently reported grade 3 or higher adverse events were diarrhea (26.6%), fatigue (15.5%), nausea (20%), and vomiting (13.3%). In a retrospective study of 34 patients

Full access

Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology

Edward M. Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Daniel Barocas, Rhonda Bitting, Alan Bryce, Brian Chapin, Heather H. Cheng, Anthony Victor D’Amico, Neil Desai, Tanya Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Shilpa Gupta, Thomas Guzzo, Joseph E. Ippolito, Michael R. Kuettel, Joshua M. Lang, Tamara Lotan, Rana R. McKay, Todd Morgan, George Netto, Julio M. Pow-Sang, Robert Reiter, Mack Roach III, Tyler Robin, Stan Rosenfeld, Ahmad Shabsigh, Daniel Spratt, Benjamin A. Teply, Jonathan Tward, Richard Valicenti, Jessica Karen Wong, Dorothy A. Shead, Jenna Snedeker, and Deborah A. Freedman-Cass

radiographic responses (36% vs 16% RECIST responses) were more common. The most common adverse reactions with abiraterone/prednisone (>5%) were fatigue (39%); back or joint discomfort (28%–32%); peripheral edema (28%); diarrhea, nausea, or constipation (22

Full access

Systemic Therapy for Small Cell Lung Cancer

Benjamin Levy, Ashish Saxena, and Bryan J. Schneider

, 2.10; 95% CI, 1.54-2.86), and nausea and vomiting (RR, 1.51; 95% CI, 1.20-1.90). Despite the Cochrane review, EP remains the most accepted initial treatment of ES-SCLC in the United States. This is supported by an acceptable and more easily managed